Abstract Number: 1468 • 2019 ACR/ARP Annual Meeting
Effects of Resistive Exercise on Fatigue and Disease Activity in Women with Primary Sjogren’s Syndrome
Background/Purpose: Fatigue is a frequent symptom of pSS, considered debilitating and the most important cause of dysfunction in these patients. The present study aimed to…Abstract Number: 1469 • 2019 ACR/ARP Annual Meeting
New 2019 SLE EULAR/ACR Classification Criteria for SLE Are Valuable for Distinguishing Patients with SLE from Patients with pSS in Daily Practice
Background/Purpose: The new 2019 SLE EULAR/ACR Classification Criteria for Systemic lupus erythematosus (SLE) have been developed to find a better equilibrium between specificity and sensitivity…Abstract Number: 1470 • 2019 ACR/ARP Annual Meeting
Health-Related Quality of Life in Primary Sjogren’s Syndrome: Insights from Using PROMIS and Comparison to ESSPRI
Background/Purpose: Background. Sjogren’s Syndrome (SS) is a chronic, autoimmune disease affecting the exocrine glands that may negatively affect health-related quality of life (HRQL). The importance…Abstract Number: 1471 • 2019 ACR/ARP Annual Meeting
Polyautoimmunity and Major Organ Involvement Prevalence in Sjögren´s Syndrome: Thyroid, Liver, Lung and Kidney as Targets. a Single Center Cross Sectional Study
Background/Purpose: Polyautoimmunity has been described to be associated with primary Sjögren´s syndrome (SjS) and the most frequent observed associated autoimmune diseases (AID) are autoimmune thyroid…Abstract Number: 1472 • 2019 ACR/ARP Annual Meeting
Primary Sjögren’s Syndrome and Development of Another Connective Tissue Disease During Follow-up
Background/Purpose: Primary Sjögren's Syndrome (pSS) is a chronic autoimmune disease characterized by lymphocytic infiltration of the exocrine glands. Is the connective tissue disease that is…Abstract Number: 1473 • 2019 ACR/ARP Annual Meeting
Syndecan-1 Is a Potential Biomarker for Salivary Glandular Function and Disease Activity in Patients with Sjögren’s Syndrome
Background/Purpose: Sjögren’s syndrome (SS) is known as autoimmune epithelitis, because epithelial cells in the glands are the primary target of disease and play a major…Abstract Number: 1474 • 2019 ACR/ARP Annual Meeting
Factors Influencing the ESSPRI Index in Primary Sjögren’s Syndrome
Background/Purpose: The ESSPRI is a validated index for measuring symptoms (pain, fatigue and dryness) in primary Sjögren’s syndrome (pSS). Herein we evaluated its association with…Abstract Number: 1475 • 2019 ACR/ARP Annual Meeting
Comparison of Different Remission Indices in Patients with Psoriatic Arthritis: A Post Hoc Analysis of Data from Phase 3 Tofacitinib Studies
Background/Purpose: An international task force has agreed that remission or low disease activity (LDA) are key treatment targets for patients (pts) with PsA, and recommends…Abstract Number: 1476 • 2019 ACR/ARP Annual Meeting
Impact of Alternate Mechanism of Action Biologics and Tofacitinib on TNF-α Inhibitor Prescribing in Psoriatic Arthritis: Results from Annual National Patient Chart Audits
Background/Purpose: TNF-α inhibitor therapy has long been the standard of care for adult patients diagnosed with moderate to severe psoriatic arthritis (PsA), though several new…Abstract Number: 1477 • 2019 ACR/ARP Annual Meeting
Golimumab Improves Direct Costs of Healthcare Utilization and Indirect Costs Within Patients with RA, PsA, and as – Analysis of a Non-Interventional Study in Germany
Background/Purpose: Rheumatic diseases are associated with pain, loss of functionality, fatigue, hospitalization, sick leave, and work disability. This results in high economic burden for patients…Abstract Number: 1478 • 2019 ACR/ARP Annual Meeting
Systematic Literature Review and Network Meta-Analysis Comparing Incidence of Uveitis and IBD in Axial Spondyloarthritis Patients Treated with Anti-TNF versus Anti-IL17A in Placebo Controlled Randomized Trials
Background/Purpose: Inflammatory bowel diseases (IBD) and anterior uveitis (AU) are frequent extra-articular features of axial spondyloarthritis (axSpA). Although effect of anti-TNF on IBD and AU…Abstract Number: 1479 • 2019 ACR/ARP Annual Meeting
Multi-Symptom Impact on the EQ5D Index in Bio-naïve Active Psoriatic Arthritis Patients: An Analysis Through Week 24 of the GO-VIBRANT Study
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by peripheral arthritis, axial inflammation, dactylitis, enthesitis and skin and nail psoriasis. The impact of…Abstract Number: 1480 • 2019 ACR/ARP Annual Meeting
Clinical Characteristics and Treatment Profiles of Patients with Ankylosing Spondylitis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Background/Purpose: Secukinumab is the only non–tumor necrosis factor inhibitor biologic therapy approved for the treatment of ankylosing spondylitis (AS) in the United States. Patients with…Abstract Number: 1481 • 2019 ACR/ARP Annual Meeting
Real-World Use of Apremilast in Combination with Biologic Therapy in Patients with Psoriatic Arthritis: Findings from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in adult patients with active PsA despite prior use of csDMARDs and/or biologics in phase…Abstract Number: 1482 • 2019 ACR/ARP Annual Meeting
Secukinumab Provides Sustained Improvement of Enthesitis in Ankylosing Spondylitis Patients: A Pooled Analysis of Four Pivotal Phase 3 Trials
Background/Purpose: Enthesitis can be a debilitating spondyloarthritis (SpA) manifestation and the cause of pain, reduced quality of life and impaired physical function.1,2 Herein, we evaluated…
ACR Meeting Abstracts